BOFAS Abstracts Archive

You can search for abstracts by using the search bar below.
Alternatively you can browse through podium and poster presentations by selecting the year and / or type below. You can further refine your search using tags or use the search bar.

 



Categories: Abstracts, 2022, Podium

How does Cartiva interpositional arthroplasty compare to arthrodesis in the treatment of hallux rigidus? A retrospective comparative study with 12 month follow up

S. Trowbridge, T. Lewis, R. Shehata, B. Lau, S. Lyle, R. Ray

1King's College Hospital NHS Foundation Trust, King's Foot and Ankle Unit, London, United Kingdom

Background: Hallux rigidus is a common condition characterised by first metatarsophalangeal joint (MTPJ) degeneration, pain and limited range of motion (ROM). The gold standard surgical treatment is arthrodesis, providing good pain relief but sacrifices ROM. Recently the Cartiva synthetic cartilage implant (SCI) has been utilised as an interpositional arthroplasty, aiming to reduce pain whilst preserving range of motion. Current evidence for Cartiva SCI is largely based on a single cohort with mixed outcomes. We sought to evaluate the clinical outcomes of Cartiva SCI compared to arthrodesis undertaken in our centre.

Methods: Retrospective review of patients undergoing Cartiva SCI or arthrodesis for treating hallux rigidus was conducted. Preoperative arthritis was radiographically graded using the Vanore classification. Patient reported outcomes (PROMs) were assessed using EuroQol 5-dimension score (EQ-5D-5L) and Manchester-Oxford Foot Questionnaire (MOXFQ).

Results: Between 2017 and 2020 there were 33 cases (17 Cartiva, 16 arthrodesis, mean age 59.0±9.9 years) with a mean follow up of 2.3 years. For the first MTPJ arthrodesis cohort, the MOXFQ domain scores were: Index 3.9±5.8, Walking/Standing 5.1±7.6, Pain 3.2±5.0, and Social Interaction 2.6±4.0. EQ-5D-5L Index score was 0.828±0.270 and the EQ-VAS was 72.5±23.3. For the Cartiva cohort, the MOXFQ domain scores were: Index 7.7±6.0, Walking/Standing 8.9±7.9, Pain 7.1±5.0, and Social Interaction 6.4±5.4. EQ-5D-5L Index score was 0.631±0.234 and the EQ-VAS was 74.8±20.8. There was no statistically significant difference between any MOXFQ domain or EQ-5D-5L scores. However, a negative trend in MOXFQ domains was identified for the Cartiva group, as well as a reoperation rate of 23.5%.

Conclusions: The Cartiva SCI demonstrated no advantage over arthrodesis in PROMs, despite the presumed benefit of preserved ROM. A significant reoperation rate was also observed. Surgeons should be cautious in the use of this novel implant.

Previous Article How do 5-year patient reported outcomes (PROMS) of TAR compare with TKR and THR?
Next Article Hyaluronic acid injection for ankle sprains: a randomised controlled trial
Print


Click thumbnail below to view poster / thumbnail:

Archive of Abstracts

2024   -   Prize Winners  |  All Abstracts
2023   -   Prize Winners  |  All Abstracts
2022   -   Prize Winners  |  All Abstracts
2021   -   Prize Winners  
2019   -   Podium  |  Poster
2018   -   Podium  |  Poster
2017   -   Podium  |  Poster
2016   -   Podium  |  Poster
2015   -   Podium  |  Poster
2014   -   Podium  |  Poster
2013   -   Podium  |  Poster
2011   -   All Abstracts
2009   -   All Abstracts
2008   -   All Abstracts
2007   -   All Abstracts
2006   -   All Abstracts
2005   -   All Abstracts
2004   -   All Abstracts
2002   -   All Abstracts
2001   -   All Abstracts
2000   -   All Abstracts
1999   -   All Abstracts
1998   -   All Abstracts
1997   -   All Abstracts
1996   -   All Abstracts
1995   -   All Abstracts
1994   -   All Abstracts
1993   -   All Abstracts
1991   -   All Abstracts
1990   -   All Abstracts
1989   -   All Abstracts
1987   -   All Abstracts
1985   -   All Abstracts
1983   -   All Abstracts